Switching HIV-1 Infected Subjects From a Highly Active Anti-Retroviral Treatment (HAART) Regimen Dosed Twice Daily or More Frequently to a Once-Daily Regimen

NCT00135369 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: stavudine extended-release, lamivudine, efavirenz

Sponsor

Bristol-Myers Squibb